International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 191-196
| Back | Table of Contents | PDF | Mail to Author | |
Gemcitabine, Oxaliplatin and Paclitaxel (GemPOx) in Patients with Relapsed or Refractory Germ Cell Tumors After High Dose Chemotherapy, A Retrospective Single-Center Experience
Ramazan ACAR1, Ismail ERTURK1, Halil KIZILOZ2, Sezgin OKCELIK2, Birol YILDIZ1, Musa Baris AYKAN1, Gul Sema Yıldıran KESKIN1, Galip BUYUKTURAN3, Serkan AKIN4, Nuri KARADURMUS1
1University of Health Science, Gulhane Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
2Nevsehir State Hospital, Deparment of Urology, Nevsehir, TURKEY
3University of Health Science, Gulhane Faculty of Medicine, Department of Gastroenterology, Ankara, TURKEY
4Hacettepe University, Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
Keywords: Gemcitabine, Oxaliplatin, Paclitaxel, Germ cell tumors, High dose chemotherapy
Germ cell tumors are chemosensitive tumors, and patients with metastatic germ cell tumors can be cured even in the metastatic setting. There are limited treatment options for the patients who have refractory or recurrent disease after high dose chemotherapy (HDCT) with autologous stem cell transplantation. We aimed to show real-life data on health outcomes in adult patients with recurrent or refractory germ cell tumor who received the gemcitabine, oxaliplatin, and paclitaxel (GemPOx) combination regimen.We analyzed the data of 33 patients receiving GemPOx regimen after HDCT in our department between January 2016 and January 2020. Primary objectives were overall response rate (ORR), overall survival (OS), and progression-free survival (PFS). The mean age of the study group was 31.5 ± 8.2 years. Of the 33 patients, 27 (81.8%) were men. The median OS and PFS were 16 months (95% CI: 7.33-24.7) and 10 months (95% CI: 5.1-14.9), respectively. The one-year OS and PFS were 65.7% and 40%, respectively. ORR was 42.4%. Toxicity was managable.Our study demonstrates acceptable safety and efficacy of GemPOx regimen for relapsed refractory patients with germ cell tumors. GemPOx remains one of the best determined systemic treatment options for progressive germ cell tumors patients after HDCT.
Ramazan ACAR1, Ismail ERTURK1, Halil KIZILOZ2, Sezgin OKCELIK2, Birol YILDIZ1, Musa Baris AYKAN1, Gul Sema Yıldıran KESKIN1, Galip BUYUKTURAN3, Serkan AKIN4, Nuri KARADURMUS1
1University of Health Science, Gulhane Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
2Nevsehir State Hospital, Deparment of Urology, Nevsehir, TURKEY
3University of Health Science, Gulhane Faculty of Medicine, Department of Gastroenterology, Ankara, TURKEY
4Hacettepe University, Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
Keywords: Gemcitabine, Oxaliplatin, Paclitaxel, Germ cell tumors, High dose chemotherapy
Germ cell tumors are chemosensitive tumors, and patients with metastatic germ cell tumors can be cured even in the metastatic setting. There are limited treatment options for the patients who have refractory or recurrent disease after high dose chemotherapy (HDCT) with autologous stem cell transplantation. We aimed to show real-life data on health outcomes in adult patients with recurrent or refractory germ cell tumor who received the gemcitabine, oxaliplatin, and paclitaxel (GemPOx) combination regimen.We analyzed the data of 33 patients receiving GemPOx regimen after HDCT in our department between January 2016 and January 2020. Primary objectives were overall response rate (ORR), overall survival (OS), and progression-free survival (PFS). The mean age of the study group was 31.5 ± 8.2 years. Of the 33 patients, 27 (81.8%) were men. The median OS and PFS were 16 months (95% CI: 7.33-24.7) and 10 months (95% CI: 5.1-14.9), respectively. The one-year OS and PFS were 65.7% and 40%, respectively. ORR was 42.4%. Toxicity was managable.Our study demonstrates acceptable safety and efficacy of GemPOx regimen for relapsed refractory patients with germ cell tumors. GemPOx remains one of the best determined systemic treatment options for progressive germ cell tumors patients after HDCT.
| Back | Table of Contents | PDF | Mail to Author | |